NEW YORK (AP) -- Biotech drugmaker Amgen and Illumina, a maker of genetic testing equipment, said Wednesday they are developing a test that will identify patients who might be helped by Amgen's colon cancer drug Vectibix.
Vectibix is approved as a treatment for colorectal cancer that has spread and hasn't responded to chemotherapy. It's intended for patients who tend to have a less aggressive form of the cancer: the drug is not indicated for those with a genetic mutation that is associated with more aggressive cancers and lower survival rates. Amgen and Illumina want to develop a test that will determine whether patients have that mutation.
The companies said the test will run on Illumina's MiSeqDx sequencing system. Financial terms of their partnership weren't disclosed.
Shares of Amgen, based in Thousand Oaks, Calif., rose 79 cents to close at $118.51 Wednesday. Shares of San Diego-based Illumina fell 39 cents to $121.12.
- Health Care Industry
- colon cancer
- genetic mutation